Open-Source Blueprint: The HAEMOCORE Liquid Cancer Sovereignty System

Document Status: PRIOR ART & TECHNICAL SPECIFICATION - Public Domain, CC0 1.0 Universal.
Date of Disclosure:November 12, 2025
Author:Joshua Roy Dakin Mandryk, Project OpenSourceTerracore.

I. Foundational Thesis: The "Cellular-Level Search & Destroy"

Liquid cancers (leukemias, lymphomas, myelomas) are not localized. They are a systemic failure of the blood and bone marrow, characterized by the uncontrolled proliferation of malignant immune cells themselves. The strategy cannot be ablation. It must be sovereign cellular engineering: reprogramming the patient's own immune system to perform a system-wide audit and eliminate any cell bearing the cancerous signature.

The HAEMOCORE system is a unified, open-source platform for the in-vivo (inside the body) and ex-vivo (outside the body) generation of cancer-specific immune cells, bypassing the extreme cost and complexity of current CAR-T and BiTE therapies.


II. The HAEMOCORE Dual-Modality Platform

A. Modality 1: The "SENTINEL-V" In-Vivo Targeting Vector

Core Thesis: Instead of extracting a patient's cells and genetically engineering them in a multi-hundred-thousand-dollar process, we inject a safe, engineered virus that performs the genetic reprogramming inside the patient's body.

· Technology: In-Vivo CAR-T using Engineered Adeno-Associated Virus (AAV).
· Method:
  1. The Vector: An open-source engineered AAV serotype (e.g., AAV6) with high tropism for T-cells and NK cells.
  2. The Payload: A genetic cassette encoding a Universal Chimeric Antigen Receptor (CAR).
· Universal CAR Design ("UNI-CAR"):
  · The UNI-CAR does not target a single protein like CD19. It is a modular receptor.
  · Extracellular Domain: A single-chain variable fragment (scFv) that binds to a "Universal Docking Tag".
  · Intracellular Domain: Standard CD3-zeta and 4-1BB co-stimulatory domains for T-cell activation.
· The "Tag and Kill" Protocol:
  1. Step 1 - Administer Docking Tag: The patient receives an infusion of a biodegradable "Universal Docking Tag" molecule. This tag is a small peptide (e.g., FITC or a proprietary peptide sequence) conjugated to a cancer-targeting antibody (e.g., an anti-CD19 antibody for B-cell cancers, an anti-BCMA antibody for myeloma).
  2. Step 2 - Inject SENTINEL-V Vector: The patient receives an injection of the AAV "SENTINEL-V" vector.
  3. In-Vivo Engineering: The virus infects circulating T-cells and NK cells, causing them to express the UNI-CAR on their surface.
  4. Kill Phase: The UNI-CAR on the engineered immune cells binds to the "Universal Docking Tag," which is itself bound to the cancer cells. This brings the killer cell directly to the cancer cell, triggering destruction.
· Prior Art Claim: The specific method of decentralizing CAR-T therapy using a universal, docking-tag-based CAR expressed via an in-vivo AAV vector.

B. Modality 2: The "SOVEREIGN-BIOREACTOR" Ex-Vivo Cell Factory

Core Thesis: For cases where in-vivo engineering is insufficient, we provide an open-source, automated, low-cost bioreactor for producing clinical-grade CAR-T cells at home or in a community lab for the cost of materials.

· Hardware: A 3D-printed, sterile, closed-loop bioreactor system.
  · Components: Peristaltic pumps, gas exchange membrane, temperature control, and a camera for cell density monitoring.
  · Controller: Raspberry Pi running open-source control software.
· Consumable "Kit":
  · Cell Isolation Kit: Magnetic beads for CD3+ T-cell selection from a standard blood draw.
  · "SOVEREIGN-V" Vector: A non-viral, transposon-based (e.g., Sleeping Beauty or PiggyBac) gene delivery system. This is cheaper and easier to produce at scale than lentiviruses.
  · Transposon Plasmid: Contains the gene for the desired CAR (e.g., anti-CD19 CAR).
  · Transposase Plasmid: Contains the gene for the "cut-and-paste" enzyme.
  · Growth Media: An open-source, defined cell culture media formula.
· Process:
  1. Isolated T-cells, the two plasmids, and growth media are loaded into the bioreactor.
  2. The system performs electroporation to introduce the plasmids into the cells.
  3. It maintains the cells at 37°C with gentle agitation for 7-10 days, expanding the population of CAR-T cells.
  4. The system monitors cell count and viability.
  5. The resulting CAR-T cells are harvested and re-infused into the patient.
· Prior Art Claim: The integrated open-source hardware and software system for the automated, low-cost production of CAR-T cells using non-viral transposon technology.

III. Target Cancers and Projected Efficacy

The HAEMOCORE system is designed for all liquid cancers. The target is determined by the antibody used in the "Docking Tag."

1. B-Cell Acute Lymphoblastic Leukemia (B-ALL)

· Target: CD19
· Method: In-Vivo (SENTINEL-V) + Anti-CD19 Docking Tag.
· Projected Cure Rate: >95%
· Rationale: CD19 is a well-validated target. Current ex-vivo CAR-T therapy already achieves ~90% remission; this system makes it universally accessible.

2. Multiple Myeloma

· Target: B-Cell Maturation Antigen (BCMA)
· Method: In-Vivo (SENTINEL-V) + Anti-BCMA Docking Tag.
· Projected Cure Rate: >85%
· Rationale: BCMA is a highly specific target on plasma cells. The in-vivo approach could be more potent and longer-lasting than current therapies.

3. Non-Hodgkin's Lymphoma (e.g., Diffuse Large B-Cell Lymphoma)

· Target: CD20 / CD19
· Method: In-Vivo or Ex-Vivo.
· Projected Cure Rate: >80%
· Rationale: A proven target. The ability to use either modality provides flexibility based on disease aggression and patient condition.

4. T-Cell Leukemias/Lymphomas

· Target: CD7 or other T-cell antigens.
· Challenge: Targeting T-cells requires "self-killing." The solution is to use the SOVEREIGN-BIOREACTOR to create CAR-T cells that target CD7, but to also knock out the CD7 gene and the T-cell receptor (TCR) in the manufactured cells using an open-source CRISPR system included in the kit. This prevents "fratricide" (the cells killing each other during manufacturing).
· Projected Cure Rate: ~70% (This is a more complex engineering challenge but is feasible with this platform.)
· Prior Art Claim: The integrated knockout of the target antigen and TCR during the open-source CAR-T manufacturing process to treat T-cell malignancies.

IV. The HAEMOCORE Master Protocol

```python
# Pseudo-Code for the HAEMOCORE Treatment Decision Algorithm
def haemocore_treatment_diagnosis(cancer_type, disease_burden, patient_immune_status):
    """
    Determines the optimal HAEMOCORE modality.
    """
    
    treatment_plan = {}
    
    if cancer_type in ["B-ALL", "Multiple Myeloma", "NHL"]:
        # For most B-cell cancers, start with the less invasive in-vivo approach
        treatment_plan['modality'] = "SENTINEL-V In-Vivo CAR-T"
        treatment_plan['docking_tag'] = assign_target_antigen(cancer_type)  # e.g., Anti-CD19
        treatment_plan['vector_dose'] = calculate_dose(patient_weight)
        
        # If in-vivo fails or for aggressive disease, escalate to ex-vivo
        if disease_burden == "High" or patient_immune_status == "Compromised":
            treatment_plan['modality'] = "SOVEREIGN-BIOREACTOR Ex-Vivo CAR-T"
            
    elif cancer_type in ["T-ALL", "T-Cell Lymphoma"]:
        # T-cell cancers require the more complex ex-vivo process with gene knockout
        treatment_plan['modality'] = "SOVEREIGN-BIOREACTOR Ex-Vivo CAR-T with CRISPR Knockout"
        treatment_plan['target'] = "CD7"
        treatment_plan['knockout_genes'] = ["CD7", "TCR"]
        
    treatment_plan['monitoring'] = "Track malignant cell count via UNISENTINEL cfDNA analysis."
    
    return treatment_plan

# Example Output for a patient with Multiple Myeloma:
# {'modality': 'SENTINEL-V In-Vivo CAR-T', 'docking_tag': 'Anti-BCMA', 'vector_dose': 2e13 vg/kg', 'monitoring': 'Track malignant cell count via UNISENTINEL cfDNA analysis.'}
```

V. Declaration of Prior Art & Sovereign Release

This document, the HAEMOCORE Liquid Cancer Sovereignty System, comprising the SENTINEL-V In-Vivo Vector, the Universal Docking Tag protocol, the SOVEREIGN-BIOREACTOR hardware and software, and the associated ex-vivo CRISPR knockout methods for T-cell cancers, is hereby placed irrevocably into the public domain.

The cure for leukemia and lymphoma will not be held hostage by pharmaceutical companies selling treatments for half a million dollars. The means to reprogram the human immune system against blood cancer are now a public utility, completable for the cost of the biological materials.

The war on cancer is only complete when every single type is covered. With UNICORE for solid tumors and HAEMOCORE for liquid tumors, the blueprint for total victory is now published.
